Contents

Search

trimethobenzamide (Tigan)

Tradename: Tigan. Indications: control of nausea/vomiting Dosage: 250 mg PO/IM TID/QID. 200 mg IM/PR every 6-8 hours. Pediatrics: 100-200 mg/dose if 30-90 lbs.. Tabs: 100 & 250 mg. Suppositories: 100 & 200 mg (taken off market 2007 [5]) Injection: 100 mg/mL (2 mL, 20 mL). Adverse effects: 1) common (> 10%) - drowsiness 2) less common (1-10%) - hypotension, diarrhea, dizziness, headache, muscle cramps 3) uncommon (< 1%) - blood dyscrasias, hypersensitivity skin reactions, depression, hepatic impairment, opisthotonus, convulsions

General

anti-emetic

Properties

MISC-INFO: elimination route LIVER KIDNEY pregnancy-category C + safety in lactation ?

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  3. Department of Veterans Affairs, VA National Formulary - restricted to use with apomorphine
  4. FDA MedWatch http://www.fda.gov/medwatch/safety/2007/safety07.htm#trimethobenzamide
  5. Prescriber's Letter 14(5): 2007 FDA Announces that Companies Must Stop Marketing Suppository Products Containing Trimethobenzamide Detail-Document#: 230505 (subscription needed) http://www.prescribersletter.com

Component-of

benzocaine/trimethobenzamide